Literature DB >> 29666116

Critical influences on the pathogenesis of follicular lymphoma.

Ralf Küppers1, Freda K Stevenson2.   

Abstract

The development of follicular lymphoma (FL) from a founder B cell with an upregulation of B-cell lymphoma 2 (BCL2), via the t(14;18) translocation, to a proliferating clone, poised to undergo further transformation to an aggressive lymphoma, illustrates the opportunistic Darwinian process of tumorigenesis. Protection against apoptosis allows an innocent cell to persist and divide, with dangerous accumulation of further mutational changes, commonly involving inactivation of chromatin-modifying genes. But this is not all. FL cells reflect normal B cells in relying on expression of surface immunoglobulin. In doing so, they add another supportive mechanism by exploiting the natural process of somatic hypermutation of the IGV genes. Positive selection of motifs for addition of glycan into the antigen-binding sites of virtually all cases, and the placement of unusual mannoses in those sites, reveals a posttranslational strategy to engage the microenvironment. A bridge between mannosylated surface immunoglobulin of FL cells and macrophage-expressed dendritic cell-specific ICAM-3-grabbing nonintegrin produces a persistent low-level signal that appears essential for life in the hostile germinal center. Early-stage FL therefore requires a triad of changes: protection from apoptosis, mutations in chromatin modifiers, and an ability to interact with lectin-expressing macrophages. These changes are common and persistent. Genetic/epigenetic analysis is providing important data but investigation of the posttranslational landscape is the next challenge. We have one glimpse of its operation via the influence of added glycan on the B-cell receptor of FL. The consequential interaction with environmental lectins illustrates how posttranslational modifications can be exploited by tumor cells, and could lead to new approaches to therapy.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29666116     DOI: 10.1182/blood-2017-11-764365

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution.

Authors:  Mariette Odabashian; Emanuela Carlotti; Shamzah Araf; Jessica Okosun; Filomena Spada; John G Gribben; Francesco Forconi; Freda K Stevenson; Mariarita Calaminici; Sergey Krysov
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

2.  Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.

Authors:  Fangyang Wang; Damián Gatica; Zhang Xiao Ying; Luke F Peterson; Peter Kim; Denzil Bernard; Kamlai Saiya-Cork; Shaomeng Wang; Mark S Kaminski; Alfred E Chang; Tycel Phillips; Daniel J Klionsky; Sami N Malek
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

3.  Follicular lymphoma-associated mutations in the V-ATPase chaperone VMA21 activate autophagy creating a targetable dependency.

Authors:  Fangyang Wang; Ying Yang; Gabriel Boudagh; Eeva-Liisa Eskelinen; Daniel J Klionsky; Sami N Malek
Journal:  Autophagy       Date:  2022-03-24       Impact factor: 13.391

Review 4.  Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

5.  PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.

Authors:  Neus Serrat; Martina Guerrero-Hernández; Alba Matas-Céspedes; Anella Yahiaoui; Juan G Valero; Ferran Nadeu; Guillem Clot; Miriam Di Re; Marc Corbera-Bellalta; Laura Magnano; Alfredo Rivas-Delgado; Anna Enjuanes; Silvia Beà; Maria C Cid; Elías Campo; Joan Montero; Daniel J Hodson; Armando López-Guillermo; Dolors Colomer; Stacey Tannheimer; Patricia Pérez-Galán
Journal:  Blood Adv       Date:  2020-09-08

6.  DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity.

Authors:  Beatriz Valle-Argos; Giorgia Chiodin; Dean J Bryant; Joe Taylor; Elizabeth Lemm; Patrick J Duriez; Philip J Rock; Jonathan C Strefford; Francesco Forconi; Richard W Burack; Graham Packham; Freda K Stevenson
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

7.  Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.

Authors:  Giorgia Chiodin; Joel D Allen; Dean J Bryant; Philip Rock; Enrica A Martino; Beatriz Valle-Argos; Patrick J Duriez; Yasunori Watanabe; Isla Henderson; James S Blachly; Katy J McCann; Jonathan C Strefford; Graham Packham; Teunis B H Geijtenbeek; Carl G Figdor; George W Wright; Louis M Staudt; Richard Burack; Thomas A Bowden; Max Crispin; Freda K Stevenson; Francesco Forconi
Journal:  Blood       Date:  2021-10-28       Impact factor: 25.476

Review 8.  The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.

Authors:  Takashi Watanabe
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

Review 9.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

10.  Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.

Authors:  Joe Taylor; Alison M Yeomans; Graham Packham
Journal:  Explor Target Antitumor Ther       Date:  2020-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.